Venetoclax (Venclyxto®)
Dokument
Fact Sheet
Spezifizierung
Akute Myeloische Leukämie (AML)
» neu diagnostiziert, ungeeignet für intensive Chemotherapie
» in Kombination mit Azacitidin
Stand
Januar 2021
Dies ist die aktuell gültige Version des Dokuments
1Venetoclax, AML, newly diagnosed, ineligible for intensive chemotherapy, in combination with Azacitidine
1 N - number of patients2 RR - remission rate, in %5 OS - overall survival in months7 SAE - serious adverse events, CTCAE grade 3/48 EFS - Event-Free Survival14 results for control, results for new therapy15 hazard ratio for new therapy19 Complete Remission Rate (CR + CRi)
